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To the editor.  
The majority of Philadelphia-positive chronic 
myeloid leukemia (CML) patients carry a t(9;22) 
translocation characterized by chromosomal 
breakpoints located on exon 13 or 14 of the BCR gene 
and exon 2 of the ABL1 gene (e13a2 or e14a2). This 
translocation generates a fusion gene whose 
epidemiology has been recently evaluated by the 
International BCR-ABL1 Study Group.1 It has been 
reported that the type of transcript influences the rate of 
complete cytogenetic response, the rate of major/deep 
molecular response, and the time needed to obtain major 
molecular response (MMR) during first-line imatinib or 
nilotinib treatment. Worldwide experiences also report 
inferior overall survival, leukemia related survival, 
progression-free survival and transformation-free 
survival in e13a2 patients, but this statement has not 
been confirmed in all studies.2-5 
Type of transcript is of interest also in the field of 
treatment-free remission (TFR), which is the current 
goal of all hematologists who treat CML, although not 
all reports on discontinuation take into consideration this 
variable. 
In rare cases of CML, breakpoints on chromosomes 
9 and 22 occur in unusual regions, giving rise to atypical 
fusion transcripts. These transcripts, including e13a3, 
e14a3, e1a3, e19a2, e8a2, are not amplified by 
quantitative Real-Time PCR (RT-qPCR), which is the 
standardized and recommended method of molecular 
response evaluation. Current recommendations and 
guidelines consider the possibility to perform RT-qPCR 
on BCR-ABL1 as one of the criteria to meet to pursue 
tyrosine kinases inhibitors (TKI) stop both in clinical 
trials and in everyday practice as well.6, 7 
Nowadays, disease monitoring in atypical transcripts 
patients is performed routinely by non-quantitative 
Nested PCR, providing only an idea of their minimal 
residual disease (MRD) status. 
Not having certainties about their biological 
behavior, due to their rarity, the lack of quantitative 
information about their molecular response 
automatically excludes patients with atypical transcripts 
from prospective protocols on TKI discontinuation. 
We retrospectively collected seven patients with 
chronic-phase CML carrying rare atypical transcripts, 
identified by Sanger sequencing,8 who discontinued TKI 
for various reasons, such as severe comorbidities, 
toxicity, or patient request (Table 1).  
 
Table 1. Patients' features. 
Patient Transcript Time on TKI before stop (months) Treatment 
Duration of MMR 
before stop (months) Loss of MMR TFR (months) 
1 b2a3 66 Dasatinib 48 No 55+ 
2 b3a3 195 Imatinib 92 No 19+ 
3 b3a3 46 Imatinib, Nilotinib 33 No 22+ 
4 b3a3 34 Imatinib 30 No 77+ 
5 e8a2 107 Nilotinib, Imatinib 93 No 5+ 
6 e19a2 71 Imatinib, Nilotinib 38 No 28+ 
7 e19a2 71 Imatinib, Nilotinib 43 Yes 2 
TKI = Tyrosine kinase inhibitor; MMR = Major molecular response; TFR = Treatment free remission. 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e202066                                                         Pag. 2 / 4 
 
For this study, we defined stable Major Molecular 
Response (MMR) as an undetectable transcript at nested 
PCR in all follow-ups in the last 24 months before 
discontinuation. Molecular monitoring was usually 
performed every three months during treatment and 
every month for the first six months after TKI 
discontinuation, followed by evaluation every six weeks 
for the remaining six months and every three months 
after then.8 
Patients showed a stable MMR, and the median 
duration of treatment with TKI was 71 months (range: 
34-195), the median duration of MMR at nested PCR 
before discontinuation was 43 months (range: 30-93). 
Only one patient resumed TKI therapy two months after 
stopping due to nested PCR positivity in two 
consecutive controls. The other six patients remained 
off-treatment at last observation after a median follow-
up of 25 months (range: 5-77). Among these, five 
patients remained negative, with an undetectable 
transcript in all samples after discontinuation. Patient 3, 
who stopped the second line Nilotinib for intolerance, 
showed a fluctuation after stopping TKI between 
negative PCR and low-level positivity at the second step 
of nested PCR (2 out of 13 samples). No progressions 
occurred. All patients, including the one that resumed 
therapy, are in MMR at the last follow-up. 
Although nowadays nested PCR represents the only 
routinely accepted method to monitor molecular 
response in CML patients with atypical transcripts, the 
qualitative nature of its results is not enough in an era of 
quantitative analysis. For this reason, we used recently 
published droplet digital PCR (ddPCR) assays9 to 
quantify the BCR-ABL1 levels in 3 of 6 collected 
patients in TFR (unfortunately, for 3 of these, RNA 
samples were not available after routine diagnostic 
tests). Twenty-one follow-ups were tested after TKI 
suspension (7 for the patient 1, 8 for the patient 2, and 6 
for the patient 3), and results were reported in Figure 1 
and Table 2.  
All the tested follow-ups showed a BCR-
ABL1/ABL1 percentage lower than 0.1% during all the 
TFR periods; in some points, %BCR-ABL1/ABL1 
achieve values lower than 0.01%, and in 6 follow-ups 
BCR-ABL1 levels resulted undetectable (0%). Our data 
in these three patients confirmed with quantitative 
information the achievement of a stable MMR, 
previously defined only by qualitative data (nested 
PCR). 
To our knowledge, there are no reports in the 
literature about patients with atypical transcripts who 
discontinued therapy. Although current guidelines do 
not recommend discontinuation for patients lacking a 
standardized quantitative method for response 
monitoring, we observed that our small cohort stopped 
 
Figure 1: Monitoring by ddPCR of BCR-ABL1 levels in 3 CML patients with atypical transcripts during the treatment-free remission (TFR) 
phase. Percentage of BCR-ABL1/ABL1 was reported on y-axis, while the time of follow-up after TFR was on x-axis and was indicated in 
months. 
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Table 2. %BCR-ABL1/ABL1 levels in 3 CML patients with atypical transcript monitored with ddPCR. 
Sample Months after TFR ddPCR %BCR-ABL1/ABL1 
Patient 1 4 0.016 
Patient 1 8 0.060 
Patient 1 36 0.000 
Patient 1 39 0.014 
Patient 1 48 0.000 
Patient 1 54 0.006 
Patient 1 58 0.009 
Patient 1 69 0.032 
Patient 2 1 0.000 
Patient 2 2 0.006 
Patient 2 3 0.004 
Patient 2 16 0.000 
Patient 2 19 0.009 
Patient 2 25 0.000 
Patient 2 32 0.018 
Patient 3 18 0.022 
Patient 3 22 0.011 
Patient 3 26 0.016 
Patient 3 31 0.007 
Patient 3 33 0.013 
Patient 3 35 0.000 
TFR: Treatment free remission. 
 
the treatment successfully.  
In this particular moment where CML care is focused 
on TKI discontinuation, it seems rather important to us 
to raise consciousness on the possibility to extend the 
policy of withdrawing TKI even in carefully selected 
patients harboring atypical transcripts. The rapid 
evolution of molecular technologies in the last years, in 
particular the use of ddPCR, could help the exploration 
of TFR opportunity also in these rare cases and could 
pave the way to study how the atypical transcripts affect 
treatment response. 
In our opinion, this leads to two important matters of 
debate: first, may qualitative analysis suffice, at least in 
a specific setting, for MRD monitoring? This could be 
of interest to all low-income countries that cannot afford 
to perform RT-qPCR during treatment nor 
discontinuation. Second, is it plausible to assume that 
patients who carried the atypical transcript may also 
have the opportunity to stop treatment? Although our 
cohort is limited, these patients behave as "standard 
breakpoints carriers" in terms of survival and 
progression during therapy.  Furthermore, among our 
cases was also present one patient with fluctuation of 
BCR-ABL1 levels during the TFR phase, which was not 
at the end associated with relapse. Although the 
definition of fluctuation cannot be the same of the A-
STIM due to the lacking of the MMR threshold to 
consider, we observed that, as in the mentioned study, 
the occurring of this pattern of positive values of BCR-
ABL1 did not impair the successfulness of 
discontinuation.10 
Although our data are encouraging and represent a 
preliminary step to consider the possibility of TKI 
discontinuation also for these patients, further reports 
are of course needed to make our observations more 
reliable: the increase in the number of cases we were 
able to collect, as well as the application of new 
quantitative technologies, such as digital PCR, for the 
MRD quantification.  
To date, there are no standardized primers and probes 
set to monitor patients with atypical BCR-ABL1 
transcripts with qRT-PCR, thus it is impossible to 
compare the two methods, and it is difficult to define a 
priori which is the best technique between qRT-PCR 
and ddPCR. Based on our experience and literature, 
ddPCR technology provides absolute quantification of 
target copies, without the need for standard curves; the 
massive sample partitioning enables the reliable 
measurement of small copy numbers of transcript, and 
error rates are reduced by removing the amplification 
efficiency reliance of qRT-PCR. Furthermore, recently 
published works, that compare qRT-PCR and ddPCR 
methods for the monitoring of canonical BCR-ABL1 
fusion transcripts, suggest that ddPCR could be a 
reliable and promising tool and conclude that ddPCR 
has a good agreement with qRT-PCR, but it is more 
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precise and reproducible in the quantification of very 
low BCR-ABL1 transcript levels.11-14 Lastly, a 
standardization process of BCR–ABL1 molecular 
monitoring for CML patients with rare variants by 
harmonization to an International Scale could be useful 
to define MRD levels better, compare results, and 
establish a better therapeutic strategy.  
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